The world shut down in 2020 as the pandemic had a global impact on trade and development, but the onco cell therapy industry remained resilient in the face of all of this. In spite of 69% of industry claiming that their biggest challenges in 2020 was meeting their projected timelines for their pipes, the race for bringing the first BCMA targeting CAR-T to the market is reaching a climax and next-generation cell therapies are at the front of mind for those in both industry and research.
Significant break throughs in GvHD for allogeneic treatments and in the use of alternative cell therapies mean that onco cell therapies are embedding themselves as the 5th pillar of oncology. New combination studies and manufacturing capabilities are showing even more promise for this sector, but with current treatments still having high costs of use and as there are limited patient pools, there are still challenges in both clinical and commercial use of these therapies.
The Onco Cell Therapy Summit (OCTS), November 16 – 18, Boston USA, brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to the process of translating R&D into commercially viable oncological therapies.
We’ve worked with industry partners to ensure that OCTS 2021 is dedicated to the effective translation and commercialization of research into safe and efficacious therapies and address these challenges.
Go here for more information and to register for the event.
*See the costs on the registration page.*